RxDoctor Payments Data

Gianna Sokolowski, APRN

Family · Brandon, FLNPI 1639794100

Payments from drug & device makers

$1,234in general payments, 2019–2025

Across 44 payments — averaging $28.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$350
  • Bayer$166
  • Amgen$163
  • Exact Sciences$141
  • Johnson & Johnson$120
  • Pfizer$57
  • plus $236 from 10 others

What the payments were for

  • Food & beverage$1,234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,234 in reported general payments places this provider in the 70th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$37,819
Medicare patients
119
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$40,547
MounjaroTirzepatide22$23,733
FarxigaDapagliflozin Propanediol17$18,972
Ajovy SyringeFremanezumab-Vfrm11$8,850
Repatha SureclickEvolocumab12$8,781
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,320
Mometasone Furoate11$1,020
Atorvastatin Calcium124$990
Albuterol Sulfate HfaAlbuterol Sulfate21$678
Duloxetine Hcl19$565
Omeprazole32$466
Amlodipine Besylate62$383
Rosuvastatin Calcium34$330
Levothyroxine Sodium41$281
Losartan Potassium40$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$350$40,54742 claims
AstraZenecaFarxiga$24$18,97217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 14,618 family providers in Florida.

Other family in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →